Nanton Veronica, Appleton Rebecca, Dale Jeremy, Roscoe Julia, Hamborg Thomas, Ahmedzai Sam H, Arvanitis Theodoros N, Badger Douglas, James Nicholas, Mendelsohn Richard, Khan Omar, Parashar Deepak, Patel Prashant
Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, United Kingdom.
Medical School, University of Sheffield, Sheffield, United Kingdom.
JMIR Res Protoc. 2017 Jul 28;6(7):e147. doi: 10.2196/resprot.7667.
The potential of technology to aid integration of care delivery systems is being explored in a range of contexts across a variety of conditions in the United Kingdom. Prostate cancer is the most common cancer in UK men. With a 10-year survival rate of 84%, there is a need to explore innovative methods of care that are integrated between primary health care providers and specialist teams in order to address long-term consequences of the disease and its treatment as well as to provide continued monitoring for recurrence.
Our aim was to test the feasibility of a randomized controlled trial to compare a model of prostate cancer continuing and follow-up care integration, underpinned by digital technology, with usual care in terms of clinical and cost-effectiveness, patient-reported outcomes, and experience.
A first phase of the study has included development of an online adaptive prostate specific Holistic Needs Assessment system (HNA), training for primary care-based nurses, training of an IT peer supporter, and interviews with health care professionals and men with prostate cancer to explore views of their care, experience of technology, and views of the proposed intervention. In Phase 2, men in the intervention arm will complete the HNA at home to help identify and articulate concerns and share them with their health care professionals, in both primary and specialist care. Participants in the control arm will receive usual care. Outcomes including quality of life and well-being, prostate-specific concerns, and patient enablement will be measured 3 times over a 9-month period.
Findings from phase 1 indicated strong support for the intervention among men, including those who had had little experience of digital technology. Men expressed a range of views on ways that the online system might be used within a clinical pathway. Health care professionals gave valuable feedback on how the output of the assessment might be presented to encourage engagement and uptake by clinical teams. Recruitment to the second phase of the study, the feasibility trial, commenced March 2017.
To our knowledge, this study is the first in the United Kingdom to trial an online holistic needs assessment for men with prostate cancer, with data shared between patients and primary and secondary care providers. This study addresses recommendations in recent policy documents promoting the importance of data sharing and enhanced communication between care providers as a basis for care integration. We anticipate that this model of care will ultimately provide important benefits for both patients and the National Health Service.
International Standard Randomized Controlled Trial Number (ISRCTN): 31380482; http://www.isrctn.com/ISRCTN31380482 (Archived by WebCite at http://www.webcitation.org/6s8I42u5N).
在英国,一系列背景下针对各种病症,人们正在探索技术在辅助医疗服务系统整合方面的潜力。前列腺癌是英国男性中最常见的癌症。其10年生存率为84%,因此有必要探索创新的护理方法,这种方法需整合初级医疗服务提供者和专科团队,以应对该疾病及其治疗的长期后果,并持续监测复发情况。
我们的目标是测试一项随机对照试验的可行性,该试验旨在比较一种以数字技术为支撑的前列腺癌持续护理与随访护理整合模式,与常规护理在临床和成本效益、患者报告的结果以及体验方面的差异。
研究的第一阶段包括开发一个在线适应性前列腺特异性整体需求评估系统(HNA)、对基层护理护士进行培训、培训一名信息技术同行支持者,以及与医疗保健专业人员和前列腺癌患者进行访谈,以探讨他们对护理的看法、技术体验以及对拟议干预措施的看法。在第二阶段,干预组的男性将在家中完成HNA,以帮助识别和阐明担忧,并与基层和专科护理的医疗保健专业人员分享。对照组的参与者将接受常规护理。在9个月的时间内,将对包括生活质量和幸福感、前列腺特异性担忧以及患者能力等结果进行3次测量。
第一阶段的研究结果表明,男性对该干预措施给予了大力支持,包括那些几乎没有数字技术使用经验的男性。男性对在线系统在临床路径中可能的使用方式表达了一系列观点。医疗保健专业人员就如何呈现评估结果以鼓励临床团队参与和采用提供了宝贵的反馈。2017年3月开始了该研究第二阶段——可行性试验的招募工作。
据我们所知,本研究是英国首个针对前列腺癌男性进行在线整体需求评估的试验,患者与基层和二级护理提供者之间共享数据。本研究回应了近期政策文件中关于促进数据共享以及加强护理提供者之间沟通作为护理整合基础的重要性的建议。我们预计这种护理模式最终将为患者和国民医疗服务体系带来重要益处。
国际标准随机对照试验编号(ISRCTN):31380482;http://www.isrctn.com/ISRCTN31380482(由WebCite存档于http://www.webcitation.org/6s8I42u5N)